A drug to treat severe itching in patients with Alagille syndrome should be granted a marketing authorization in the European Union under what the European Medicines Agency (EMA) termed exceptional circumstances. At its monthly meeting, the agency’s Committee for Medicinal Products for Human Use (CHMP) determined that Kayfanda (odevixibat...
.png)
Copyright © 2023 cape-breton.com. Toady's News. All Rights Reserved
